Trinity Biotech (TRIB) PT Lowered to $20 at Roth Capital

Roth Capital analyst Chris Lewis lowered his price target on Trinity Biotech (NASDAQ: TRIB) to $20.00 (from $22.00) following weak Q2 financials but maintained a Buy rating and noted the positive Troponin update.

Lewis commented, "TRIB reported disappointing 2Q results marked by African HIV softness, unfavorable Fx, and continued margin pressures. Despite the weak quarter financially, TRIB announced significant advancements for its U.S. troponin regulatory program, including the enrollment completion for the ACS and URL clinical studies. While TRIB’s core business remains limited due to a lack of near-term revenue and earnings growth catalysts, we maintain our Buy rating given our bullish stance on troponin and its expected regulatory milestones going forward."

For an analyst ratings summary and ratings history on Trinity Biotecjh click here. For more ratings news on Trinity Biotecjh click here.

Shares of Trinity Biotecjh closed at $16.57 yesterday.

You May Also Be Interested In

• Jefferies Group (JEF) PT Lowered to $83 at Oppenheimer
• Qualcomm (QCOM) PT Raised to $190 at Susquehanna
• Lake Street Downgrades Identiv, Inc. (INVE) to Hold